Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | KarMMa: idecabtagene vicleucel QoL

Michel Delforge • 15 Jun 2020
EHA 2020
Multiple Myeloma CAR-T Idecabtagene vicleucel
KarMMa

Michel Delforge, MD, PhD, of the University of Leuven, Leuven, Belgium, discusses results from the KarMMa trial (NCT03361748) which investigated the quality of life in patients with relapsed and refractory multiple myeloma treated with the BCMA-targeted CAR T-cell therapy idecabtagene vicleucel (ide-cel; bb2121). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Michel Delforge

Cevostamab in patients with triple-class refractory MM after prior BCMA-targeted bispecific antibody 2:27
Cevostamab in patients with triple-class refractory MM after prior BCMA-targeted bispecific antibody
Michel Delforge • 6 Dec 2024
RPM for early CRS detection in patients with multiple myeloma receiving bispecific antibodies 2:37
RPM for early CRS detection in patients with multiple myeloma receiving bispecific antibodies
Michel Delforge • 6 Dec 2024
The importance of the multidisciplinary team in the successful deployment of CAR-T therapies 1:18
The importance of the multidisciplinary team in the successful deployment of CAR-T therapies
Michel Delforge • 6 Dec 2024
HRQoL in heavily pretreated patients with MM treated with ide-cel or standard regimens in KarMMa-3 2:20
HRQoL in heavily pretreated patients with MM treated with ide-cel or standard regimens in KarMMa-3
Michel Delforge • 10 Dec 2023

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals